Brokerages Set aTyr Pharma, Inc. (NASDAQ:ATYR) Price Target at $20.20

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) has received an average recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $20.20.

Several research firms have weighed in on ATYR. Wells Fargo & Company lifted their target price on aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, June 20th. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a report on Wednesday, June 4th.

aTyr Pharma Price Performance

Shares of ATYR traded down $0.28 during trading hours on Friday, reaching $5.71. 4,765,514 shares of the company traded hands, compared to its average volume of 1,390,579. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $508.19 million, a PE ratio of -7.05 and a beta of 0.89. aTyr Pharma has a fifty-two week low of $1.58 and a fifty-two week high of $7.17. The stock has a fifty day simple moving average of $4.82 and a 200 day simple moving average of $3.94.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. As a group, research analysts predict that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Institutional Trading of aTyr Pharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Group One Trading LLC acquired a new position in aTyr Pharma in the fourth quarter valued at about $26,000. Victory Capital Management Inc. purchased a new position in aTyr Pharma in the fourth quarter valued at approximately $37,000. Raymond James Financial Inc. purchased a new position in aTyr Pharma in the fourth quarter valued at approximately $39,000. XTX Topco Ltd purchased a new position in shares of aTyr Pharma during the fourth quarter worth approximately $40,000. Finally, Two Sigma Advisers LP purchased a new position in shares of aTyr Pharma during the fourth quarter worth approximately $44,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.